Chronic treatments with a 5-HT 4 receptor agonist decrease amyloid pathology in the entorhinal cortex and learning and memory deficits in the 5xFAD mouse model of Alzheimer's disease, Neuropharmacology, vol.126, pp.128-141, 2017. ,
Serotonin 5-HT 6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease, J. Med. Chem, vol.57, pp.7160-7181, 2014. ,
Multi-target-directed ligands to combat neurodegenerative diseases, J. Med. Chem, vol.51, pp.347-372, 2008. ,
Activation of 5-HT 4 receptors inhibits secretion of ?-amyloid peptides and increases neuronal survival, Exp. Neurol, vol.203, pp.274-278, 2007. ,
Serotonin: a new hope in Alzheimer's disease?, ACS Chem. Neurosci, vol.6, pp.940-943, 2015. ,
, , 1994.
, -HT 4 receptor stimulation facilitates acetylcholine release in rat frontal cortex, Neuroreport, vol.5, pp.1230-1232
In vivo effects of the 5-HT 6 antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate, Br. J. Pharmacol, vol.130, pp.23-26, 2000. ,
The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus, Neuropsychopharmacology, vol.25, pp.662-668, 2001. ,
5-HT 6 receptor antagonists: potential efficacy for the treatment of cognitive impairment in schizophrenia, Curr. Pharm. Des, vol.21, pp.3739-3759, 2015. ,
Physical interaction between neurofibromin and serotonin 5-HT 6 receptor promotes receptor constitutive activity, Proc. Natl. Acad. Sci. U S A, vol.113, pp.12310-12315, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01407899
Dual-acting compounds acting as receptor ligands and enzyme inhibitors,'' in Design of Hybrid Molecules for Drug Development, pp.137-165, 2017. ,
Structure-activity relationships and computational investigations into the development of potent and balanced dual-acting butyrylcholinesterase inhibitors and human cannabinoid receptor 2 ligands with pro-cognitive in vivo profiles, J. Med. Chem, vol.61, pp.1646-1663, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01837661
Cdk5 induces constitutive activation of 5-HT 6 receptors to promote neurite growth, Nat. Chem. Biol, vol.10, pp.590-597, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01178901
Pharmacological characterization of two novel and potent 5-HT 4 receptor agonists, RS67333 and RS67506, in vitro and in vivo, Br. J. Pharmacol, vol.115, pp.1387-1392, 1995. ,
Current approaches to the treatment of Parkinson's disease, Bioorg. Med. Chem. Lett, vol.27, pp.4247-4255, 2017. ,
A new and rapid colorimetric determination of acetylcholinesterase activity, Biochem. Pharmacol, vol.7, pp.90145-90154, 1961. ,
Synergistic effect of acetylcholinesterase inhibition (donepezil) and 5-HT(4) receptor activation (RS67333) on object recognition in mice, Behav. Brain Res, vol.230, pp.304-308, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00821461
5-HT 4 receptor-mediated modulation of 5-HT release in the rat hippocampus in vivo, Br. J. Pharmacol, vol.117, pp.1475-1480, 1996. ,
Early administration of RS 67333, a specific 5-HT 4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer's disease, Front. Aging Neurosci, vol.5, p.96, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01703910
5-HT 4 receptor stimulation leads to soluble A?PP? production through MMP-9 upregulation, J. Alzheimers Dis, vol.32, pp.437-445, 2012. ,
SB-399885 is a potent, selective 5-HT 6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models, Eur. J. Pharmacol, vol.553, pp.109-119, 2006. ,
Effect of purines analogues on spontaneous alternation in mice, Psychopharmacology, vol.123, pp.250-257, 1996. ,
Investigations into the binding affinities of different human 5-HT 4 receptor splice variants, Pharmacology, vol.85, pp.224-233, 2010. ,
Therapeutic potential of 5-HT 6 receptor agonists, J. Med. Chem, vol.58, pp.7901-7912, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-02043781
Effects of 5-HT 4 receptor stimulation on basal and electrically evoked release of acetylcholine from guinea-pig myenteric plexus, Naunyn Schmiedebergs Arch. Pharmacol, vol.345, pp.270-275, 1992. ,
Modulating 5-HT 4 and 5-HT 6 receptors in Alzheimer's disease treatment, Future Med. Chem, vol.9, pp.781-795, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02043735
Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment, Proc. Natl. Acad. Sci. U S A, vol.111, 2014. ,
BIMU 1 and RS 67333, two 5-HT 4 receptor agonists, modulate spontaneous alternation deficits induced by scopolamine in the mouse, Naunyn Schmiedebergs Arch. Pharmacol, vol.367, pp.621-628, 2003. ,
5-HT 4 receptor and Alzheimer's disease: the amyloid connection, Exp. Neurol, vol.205, pp.325-329, 2007. ,
Neurochemical and electrophysiological evidence that 5-HT 4 receptors exert a state-dependent facilitatory control in vivo on nigrostriatal, but not mesoaccumbal, dopaminergic function, Eur. J. Neurosci, vol.13, pp.889-898, 2001. ,
Lack of localization of 5-HT 6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT 6 receptor-mediated acetylcholine release, Eur. J. Neurosci, vol.24, pp.1299-1306, 2006. ,
A new design for the screening of CNS-active drugs in mice, Arzneimittelforschung, vol.11, pp.1727-1734, 1971. ,
Synthesis, structure-activity relationships, and preclinical evaluation of heteroaromatic amides and 1,3,4-oxadiazole derivatives as 5-HT 4 receptor partial agonists, J. Med. Chem, vol.61, pp.4993-5008, 2018. ,
Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3? inhibitors, Angew. Chem. Int. Ed Engl, vol.54, pp.1578-1582, 2015. ,
Chronic activation of 5-HT 4 receptors or blockade of 5-HT 6 receptors improve memory performances, Behav. Brain Res, vol.293, pp.10-17, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-02043824
Influence of the 5-HT 6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT 6 receptor antagonist, J. Med. Chem, vol.46, pp.1273-1276, 2003. ,
Multi target-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT 4 R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride, J. Med. Chem, vol.58, pp.3172-3187, 2015. ,
Design, synthesis, and biological evaluation of new 5-HT 4 receptor agonists: application as amyloid cascade modulators and potential therapeutic utility in Alzheimer's disease design, J. Med. Chem, vol.52, pp.2214-2225, 2009. ,
Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat, Neuropsychopharmacology, vol.26, pp.583-594, 2002. ,
Ability of 5-HT 4 receptor ligands to modulate rat striatal dopamine release in vitro and in vivo, Br. J. Pharmacol, vol.117, pp.55-62, 1996. ,
Safety and efficacy of idalopirdine, a 5-HT 6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebocontrolled phase 2 trial, Lancet Neurol, vol.13, issue.14, p.70198, 2014. ,
Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT 4 ) partial agonist and 5-HT 6 antagonist activities, as potential treatment of Alzheimer's disease, Eur. J. Med. Chem, vol.121, pp.283-293, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-02043759
Development of a liquid chromatography/tandem mass spectrometry method for the quantitation of acetylcholine and related neurotransmitters in brain microdialysis samples, J. Pharm. Biomed. Anal, vol.44, pp.586-593, 2007. ,